Partnerships, Licensing, Investments and M&A Deals and Trends for March 2020 in Pharmaceuticals

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for March 2020 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in March 2020. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharma Intelligence Center deals database and primary and secondary research.

Scope

Analysis of the market trends for the pharmaceutical industry in the global arena.

Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

Analysis of partnership and licensing deals based on clinical stage of development of products.

Summary of the pharmaceutical deals globally in the six months.

Information on the top deals happened in the pharmaceutical industry.

Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

Enhance your decision making capability in a more rapid and time sensitive manner.

Find out the major deal performing segments for investments in your industry.

Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

Identify companies that are aggressively looking to raise capital in the market

Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

Identify growth segments and opportunities in each region within the industry.

Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1. Table of Contents

1. Table of Contents 2

1.1. List of Tables 5

1.2. List of Figures 7

2. Deal Values in Pharmaceutical and Healthcare Industry Increased in March2020 9

2.1. Pharmaceuticals & Healthcare, Deals Summary, March 2020 9

3. Pharmaceuticals & Healthcare, Global, Deal Summary, 13

3.1. Pharmaceuticals & Healthcare, Global, Deal Analysis, March 2020 13

3.2. Pharmaceuticals & Healthcare, Global, Major Deals, March 2020 14

3.2.1. Thermo Fisher Scientific to Acquire Qiagen 15

3.2.2. Gilead Sciences Acquires Forty Seven 15

3.2.3. Silence Therapeutics Enters into Collaboration with Astrazeneca 16

3.2.4. CytomX Therapeutics Enters into Agreement with Astellas Pharma 16

3.2.5. Pfizer Raises USD1.25 Billion in Public Offering of

2.625% Notes Due 2030 17

3.3. Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, March 2020 18

3.4. Pharmaceuticals & Healthcare, Global, by Type, Deal Values, March 2020 19

4. Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 20

4.1. Pharmaceuticals & Healthcare, Global, M&A, March 2020 20

4.1.1. Top M&A Deals in March 2020 21

4.1.2. Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, October 2019– March 2020 22

4.2. Pharmaceuticals & Healthcare, Global, Equity Offering Deals, March 2020 23

4.2.1. Top Equity Offering Deals in March 2020 24

4.2.2. Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, October 2019– March 2020 25

4.3. Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, March 2020 26

4.3.1. Top PE/VC Deals in March 2020 27

4.3.2. Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, March 2020 28

4.3.3. Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, March 2020 29

4.3.5. Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, October 2019–March 2020 31

4.3.7. Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, October 2019–March 2020 32

4.4. Pharmaceuticals & Healthcare, Global, Partnership Deals, March 2020 33

4.5. Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, October 2019– March 2020 34

4.6. Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), March 2020 35

4.6.1. Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, March 2020 36

4.7. Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), October 2019– March 2020 37

4.8. Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, October 2019– March 2020 39

4.9. Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), October 2019– March 2020 40

4.10. Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), October 2019– March 2020 42

5. Pharmaceuticals & Healthcare, Global, Licensing Agreements, March 2020 44

5.1. Pharmaceuticals & Healthcare, Global, Licensing Agreements, March 2020 44

5.2. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), March 2020 46

5.3. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), October 2019– March 2020 48

5.4. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), October 2019– March 2020 50

5.5. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), October 2019– March 2020 52

5.6. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), October 2019– March 2020 55

5.6.1. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, March 2020 56

5.6.2. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, March 2020 57

5.6.3. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, March 2020 58

6. Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 59

6.1. Pharmaceuticals & Healthcare, Global, Oncology Deals, March 2020 59

6.1.1. Oncology – Deals of the Month 60

6.2. Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, March 2020 62

6.2.1. Central Nervous System – Deals of the Month 63

6.3. Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, March 2020 65

6.3.1. Infectious Diseases – Deals of the Month 66

6.4. Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, March 2020 68

6.4.1. Cardiovascular – Deals of the Month 69

6.5. Pharmaceuticals & Healthcare, Global, Immunology Deals, March 2020 71

6.5.1. Immunology – Deal of the Month 72

6.6. Pharmaceuticals & Healthcare, Global, Metabolic Disorders Deals, March 2020 73

6.6.1. Metabolic– Deals of the Month 74

6.7. Pharmaceuticals & Healthcare, Global, Gastrointestinal Disorders, Deals, March 2020 75

6.7.1. Gastrointestinal – Deals of the Month 76

7. Deal Summary by Geography 77

7.1. Pharmaceuticals & Healthcare, North America Deals, March 2020 77

7.1.1. North America – Deals of the Month 78

7.2. Pharmaceuticals & Healthcare, Europe, Deals, March 2020 80

7.2.1. Europe – Deals of the Month 81

7.3. Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, March 2020 82

7.3.1. Asia-Pacific – Deals of the Month 83

7.4. Pharmaceuticals & Healthcare, Rest of the World, Deals, March 2020 85

7.4.1. Rest of the World – Deals of the Month 86

8. Pharmaceuticals & Healthcare, Global, Top Financial Advisors 88

8.1. Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, October 2019– March 2020 88

8.2. Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, October 2019– March 2020 90

9. Further Information 92

9.1. Methodology 92

9.2. About GlobalData 93

9.3. Contact Us 93

9.4. Disclosure information 93

9.5. Disclaimer 93

List of Tables

1.1. List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019– March 2020 14

Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, March 2020 14

Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), March 2020 19

Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019– March 2020 21

Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, March 2020 21

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, October 2019– March 2020 22

Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019– March 2020 24

Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, March 2020 24

Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019– March 2020 25

Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019– March 2020 27

Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, March 2020 27

Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, October 2019– March 2020 28

Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), March 2020 30

Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), October 2019– March 2020 31

Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, October 2019– March 2020 32

Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), October 2019– March 2020 33

Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2019– March 2020 34

Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2019– March 2020 35

Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), March 2020 36

Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), October 2019– March 2020 38

Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2019– March 2020 41

Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), October 2019– March 2020 43

Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019– March 2020 45

Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), October 2019– March 2020 47

Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2019– March 2020 49

Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), March 2020 51

Table 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, October 2019– March 2020 54

Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), March 2020 56

Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, March 2020 56

Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, March 2020 57

Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, March 2020 58

Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019– March 2020 60

Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019– March 2020 63

Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019– March 2020 66

Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019– March 2020 69

Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019– March 2020 72

Table 37: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019– March 2020 74

Table 38: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019– March 2020 76

Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019– March 2020 78

Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019– March 2020 81

Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019– March 2020 83

Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019– March 2020 86

Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), October 2019– March 2020 89

Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), October 2019– March 2020 91

List of Figures

1.2. List of Figures

s

Figure 1: Pharmaceuticals & Healthcare, Number of Deals by Therapy Area, March 2020 9

Figure 2: Pharmaceuticals & Healthcare, Number of Licensing Deals By Payment Mode, October 2019 – March 2020 10

Figure 3: Pharmaceuticals & Healthcare, Number of Deals by Region, March 2020 11

Figure 4: Pharmaceuticals & Healthcare, Number of Deals by Type, March 2020 12

Figure 5: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), October 2019– March 2020 13

Figure 6: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), March 2020 18

Figure 7: Pharmaceuticals & Healthcare, Global, Deal Values (%), March 2020 19

Figure 8: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), October 2019– March 2020 20

Figure 9: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, October 2019– March 2020 22

Figure 10: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), October 2019– March 2020 23

Figure 11: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2019– March 2020 25

Figure 12: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), October 2019– March 2020 26

Figure 13: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, October 2019– March 2020 28

Figure 14: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), March 2020 29

Figure 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), March 2020 30

Figure 16: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), October 2019– March 2020 31

Figure 17: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), October 2019– March 2020 33

Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2019– March 2020 34

Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2019– March 2020 35

Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), October 2019– March 2020 37

Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2019– March 2020 39

Figure 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2019– March 2020 40

Figure 23: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), October 2019– March 2020 42

Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), October 2019– March 2020 44

Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2019– March 2020 46

Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2019– March 2020 48

Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), October 2019– March 2020 50

Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, October 2019– March 2020 52

Figure 29: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), October 2019– March 2020 53

Figure 30: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), March 2020 55

Figure 31: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), October 2019– March 2020 59

Figure 32: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), October 2019– March 2020 62

Figure 33: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), October 2019– March 2020 65

Figure 34: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), October 2019– March 2020 68

Figure 35: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), October 2019– March 2020 71

Figure 36: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019– March 2020 73

Figure 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019– March 2020 75

Figure 38: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), October 2019– March 2020 77

Figure 39: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), October 2019– March 2020 80

Figure 40: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), October 2019– March 2020 82

Figure 41: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), October 2019– March 2020 85

Figure 42: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), October 2019– March 2020 88

Figure 43: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), October 2019– March 2020 90

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports